Today: 10 April 2026
Browse Category

NYSE:HUM 3 October 2025 - 27 January 2026

UnitedHealth stock tumbles nearly 20% as Medicare Advantage rate proposal rattles UNH investors

UnitedHealth stock tumbles nearly 20% as Medicare Advantage rate proposal rattles UNH investors

UnitedHealth shares fell 18.4% to $286.96 Tuesday after a U.S. proposal signaled Medicare Advantage payments would rise just 0.09% in 2027. The company warned of its first revenue drop since 1989 despite maintaining its 2026 profit outlook. CVS Health and Humana also posted sharp declines. CMS will accept comments on the proposed rates through Feb. 25.
27 January 2026
Dow Jones drops 450 points as UnitedHealth sinks on Medicare rates; confidence slumps

Dow Jones drops 450 points as UnitedHealth sinks on Medicare rates; confidence slumps

The Dow Jones fell 445 points, or 0.9%, to 48,966 in early trading, dragged down by a 20% plunge in UnitedHealth after weak Medicare payment proposals and a downbeat 2026 forecast. U.S. consumer confidence dropped to its lowest since 2014. The S&P 500 and Nasdaq rose, while Humana and CVS also tumbled. Traders watched for earnings and the Fed meeting starting Tuesday.
27 January 2026
Why UnitedHealth stock fell today: UNH slides as Medicare Advantage spotlight returns

Why UnitedHealth stock fell today: UNH slides as Medicare Advantage spotlight returns

UnitedHealth shares fell 2.3% to $331.02 in after-hours trading Friday following a MedPAC report highlighting $76 billion in projected Medicare Advantage overpayments. The drop came ahead of a long holiday weekend and the company’s earnings release set for Jan. 27. Managed-care stocks broadly declined, with Humana down 3.76% and Elevance Health off 1.85%.
17 January 2026
UnitedHealth stock drops today — what traders are watching before UNH earnings

UnitedHealth stock drops today — what traders are watching before UNH earnings

UnitedHealth shares fell 1.3% to $334.40 Friday, weighing on the Dow as managed-care stocks slid after Trump’s new healthcare proposal. The plan, which would replace insurance subsidies with direct payments to consumers, left policy details unclear and insurers under pressure. UnitedHealth will report 2025 earnings and its 2026 outlook on Jan. 27. Investors are watching for updates on government-plan costs and future guidance.
UnitedHealth stock falls despite new price targets as Wall Street eyes Jan. 27 earnings

UnitedHealth stock falls despite new price targets as Wall Street eyes Jan. 27 earnings

UnitedHealth shares fell over 2% to $340.44 Wednesday morning, erasing part of Tuesday’s gain. The drop followed analyst moves, with Bernstein raising its target to $444 and Evercore ISI starting coverage at $400. Investors await UnitedHealth’s Jan. 27 results and Medicare Advantage rate updates. Humana and Cigna also declined.
UnitedHealth stock ticks up after Barclays target hike as UNH earnings near

UnitedHealth stock ticks up after Barclays target hike as UNH earnings near

UnitedHealth shares rose 0.8% to $338.94 in late-morning trading Monday after Barclays raised its price target to $391 and reiterated an Overweight rating. Investors are watching ahead of Jan. 27, when UnitedHealth will report 2025 results and 2026 guidance. Scrutiny remains on medical-cost trends, operational review progress, and ongoing Justice Department investigations into Medicare Advantage billing.
UnitedHealth stock rises into the weekend — what UNH investors watch before Jan. 27 results

UnitedHealth stock rises into the weekend — what UNH investors watch before Jan. 27 results

UnitedHealth Group shares rose 1.9% to $336.40 Friday, trading 6.9 million shares and closing above key moving averages. The company will report full-year results and its 2026 outlook before the market opens Jan. 27. UnitedHealth remains under Justice Department investigation over billing practices. The stock is well below its 52-week high of $606.36.
UnitedHealth Group (UNH) Stock After Hours Today (Dec. 15, 2025): Key News, Analyst Forecasts, and What to Watch Before Tuesday’s Open

UnitedHealth Group (UNH) Stock After Hours Today (Dec. 15, 2025): Key News, Analyst Forecasts, and What to Watch Before Tuesday’s Open

UnitedHealth (UNH) closed Monday down 0.22% at $341.10 and slipped to $340.14 after hours. The move followed Fitch’s downgrade of rival Humana, citing higher medical costs and weaker Medicare Advantage bonuses. UNH traded 6.3 million shares in a $337–$344.96 range. Industry commentary remains focused on rising expenses and regulatory pressure.
Humana Stock (HUM) Outlook December 4, 2025: Earnings Beat, Legal Risks and 2026 Medicare Advantage Forecast

Humana Stock (HUM) Outlook December 4, 2025: Earnings Beat, Legal Risks and 2026 Medicare Advantage Forecast

Humana shares traded in the mid-$250s on December 4, down 12% over the past year and 18% below their September high. The stock is up just 1.3% year to date, lagging the SPDR S&P Health Care Services ETF’s nearly 20% gain. Institutional investors, including Norges Bank, increased stakes in 2025, with about 92% of shares now institutionally held. Regulatory headlines and guidance changes have driven sharp price swings.
Humana (HUM) Stock on Nov 5, 2025: Earnings Beat, Outlook Trimmed – Full Analysis

Humana (HUM) Stock on Nov 5, 2025: Earnings Beat, Outlook Trimmed – Full Analysis

Humana shares traded at $269 on Nov 5, 2025, after Q3 earnings beat expectations with adjusted EPS of $3.24 and revenue of $32.65 billion. The company reaffirmed full-year adjusted EPS guidance but cut its GAAP forecast due to higher medical costs. Shares fell 4% pre-market. Humana projects a 7% drop in Medicare Advantage membership for 2025 after a major plan’s star rating downgrade.
Humana Hit Hard: Judge Upholds Medicare Advantage Star Cut, Stock Slides

Humana Hit Hard: Judge Upholds Medicare Advantage Star Cut, Stock Slides

A federal judge on Oct. 14 upheld the U.S. government’s downgrade of Humana’s 2025 Medicare Advantage star rating from 4.5 to 3.5 stars, dismissing Humana’s lawsuit. The ruling leaves about 45% of Humana’s Medicare Advantage members in lower-rated plans and could cost the company an estimated $1 billion in lost federal bonus payments next year. Humana shares fell 3–4% on the news. The company said it may appeal.
15 October 2025
Record Highs, AI Hype, and a Shutdown: Key Takeaways from U.S. Stock Markets (Oct 3–4, 2025)

Record Highs, AI Hype, and a Shutdown: Key Takeaways from U.S. Stock Markets (Oct 3–4, 2025)

The S&P 500 and Dow closed at record highs Friday, with the Dow up 0.5% despite a third day of the U.S. government shutdown. The September jobs report was delayed, but traders expect a Fed rate cut in late October. Utilities and health insurers led gains, while tech stocks lagged. Palantir dropped 7.5% after a U.S. Army memo flagged security issues; Applied Materials fell 3% on China export curbs.
Humana (HUM) Stock Skyrockets on Medicare News – What Investors Must Know Today

Humana Stock Skyrockets as Medicare Advantage News Ignites Rally

Humana shares closed at $283.72 on Oct. 3, 2025, up 10.6% after stronger-than-expected Medicare Advantage metrics and improved 2026 plan benefits. The company reaffirmed 2025 EPS guidance and raised its revenue outlook to at least $128 billion. Humana will reduce its Medicare Advantage footprint to 85% of U.S. counties next year. Trading volume spiked as investors reacted to the news.
3 October 2025
Humana (HUM) Stock Skyrockets on Medicare News – What Investors Must Know Today

Humana (HUM) Stock Skyrockets on Medicare News – What Investors Must Know Today

Humana shares jumped over 6% to $272.05 midday Oct 3 after the company reported a sharp rise in Medicare Advantage star ratings for 2026. The stock rebounded from last week’s drop, which followed news of Humana cutting its Medicare Advantage footprint. Wall Street consensus remains neutral, with a $289 average price target. Year-to-date, shares are flat and about 19% below their 52-week high.
3 October 2025

Stock Market Today

  • Byrna (BYRN) Shares Drop 20.5% After Q1 Earnings Miss Expectations
    April 9, 2026, 8:37 PM EDT. Byrna (NASDAQ:BYRN) stock fell 20.5% following its first-quarter 2026 results that missed analyst expectations despite 10.9% revenue growth to $29.05 million. Earnings per share came in at $0.03 versus estimates of $0.07, down from $0.07 a year earlier. Operating margin shrank to 3.2% from 6.5%, pressured by rising expenses. The market reacted sharply to the decline in profitability. Byrna shares are highly volatile, with notable price swings this year alongside broader economic worries. The stock has dropped 57.6% year-to-date and trades 78.9% below its 52-week high of $33.56. Investors remain cautious amid slowing U.S. economic growth and inflation concerns. Byrna's sharp decline highlights investor sensitivity to earnings misses and profit erosion despite sales gains.

Latest article

MARA Holdings Stock Rises Even After Target Cut as Bitcoin Miner Leans Harder Into AI

MARA Holdings Stock Rises Even After Target Cut as Bitcoin Miner Leans Harder Into AI

9 April 2026
MARA Holdings shares rose 1.7% to $9.67 Thursday despite Cantor Fitzgerald cutting its price target to $10. The company recently sold 15,133 bitcoin for $1.1 billion and agreed to repurchase $1 billion in convertible notes at a discount. MARA is expanding into AI and cloud infrastructure, but fourth-quarter revenue fell 6% and it posted a $1.7 billion net loss.
CoreWeave secures fresh $21 billion Meta AI deal as debt push raises stakes

CoreWeave secures fresh $21 billion Meta AI deal as debt push raises stakes

9 April 2026
Meta Platforms signed a new $21 billion deal with CoreWeave for AI cloud computing capacity through 2032, according to a securities filing. CoreWeave shares rose 3.4% in after-hours trading. The agreement adds to a $14.2 billion commitment disclosed last September. CoreWeave also launched $3 billion in convertible notes and upsized a senior-notes deal to $1.75 billion.
Tesla Revives Cheaper EV Push With New Compact SUV as Sales Pressure Builds

Tesla Revives Cheaper EV Push With New Compact SUV as Sales Pressure Builds

9 April 2026
Tesla is developing a lower-cost compact SUV, with initial production planned for Shanghai, Reuters reported Thursday. The company built 408,386 vehicles and delivered 358,023 in the first quarter, leaving its widest gap in at least four years. Reuters said the new SUV likely will not reach production this year. Tesla did not respond to questions about the project.
NIO ES9 Price Starts at 528,000 Yuan as Flagship SUV Bet Faces China EV Slump

NIO ES9 Price Starts at 528,000 Yuan as Flagship SUV Bet Faces China EV Slump

9 April 2026
NIO opened pre-orders for its ES9 flagship SUV Thursday, pricing it at 528,000 yuan with battery or 420,000 yuan under its Battery-as-a-Service plan. March deliveries rose 136% year-on-year, but NIO’s U.S. shares fell 4.9% after the announcement. The ES9 enters a shrinking premium SUV market in China, competing with Li Auto and Aito. CEO William Li warned chip shortages could add up to 10,000 yuan per vehicle.
Plug Power Stock Climbs After 2026 Profit Push, Up to $200M Cost-Cut Plan

Plug Power Stock Climbs After 2026 Profit Push, Up to $200M Cost-Cut Plan

9 April 2026
Plug Power shares rose 2.5% to $2.715 Thursday after the company reaffirmed its target of positive EBITDAS by end-2026 and projected up to $200 million in savings from Project Quantum Leap. The update followed a major electrolyzer project win in Quebec and investor meetings in Toronto and Montreal. Plug reported 2025 revenue of $710 million and a fourth-quarter gross profit of $5.5 million.
Go toTop